Do analysts prefer ACTU or ICCC?

Actuate Therapeutics presently has a consensus target price of $10.50, suggesting a potential upside of 1,444.12%. Given Actuate Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Actuate Therapeutics is more favorable than ImmuCell. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Actuate Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 ImmuCell 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts recommend ACTU or NTRB?

Actuate Therapeutics presently has a consensus target price of $10.50, indicating a potential upside of 1,444.12%. Given Actuate Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Actuate Therapeutics is more favorable than Nutriband. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Actuate Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Nutriband 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has higher valuation & earnings, ACTU or ALDX?

Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Actuate Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Actuate Therapeutics N/A N/A -$22.23M -$0.87 N/A Aldeyra Therapeutics N/A N/A -$33.85M -$0.39 N/A

Is ACTU or ALDX more profitable?

Aldeyra Therapeutics' return on equity of -53.14% beat Actuate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Actuate Therapeutics N/A -346.19% -178.40% Aldeyra Therapeutics N/A -53.14% -34.94%

Actuate Therapeutics (ACTU) Competitors

$0.68 -0.05 (-7.05%)

As of 09:39 AM Eastern

Compare

ACTU vs. ICCC, NTRB, ALDX, FBIO, and VRCA

Should you buy Actuate Therapeutics stock or one of its competitors? Actuate Therapeutics's main competitors and comparable companies include ImmuCell (ICCC), Nutriband (NTRB), Aldeyra Therapeutics (ALDX), Fortress Biotech (FBIO), and Verrica Pharmaceuticals (VRCA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Actuate Therapeutics compare to ImmuCell?

Actuate Therapeutics (NASDAQ:ACTU) and ImmuCell (NASDAQ:ICCC) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.

ImmuCell has a net margin of 2.57% compared to Actuate Therapeutics' net margin of 0.00%. ImmuCell's return on equity of 2.69% beat Actuate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actuate Therapeutics	N/A	-346.19%	-178.40%
ImmuCell	2.57%	2.69%	1.76%

Actuate Therapeutics presently has a consensus target price of $10.50, suggesting a potential upside of 1,444.12%. Given Actuate Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Actuate Therapeutics is more favorable than ImmuCell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actuate Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
ImmuCell	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

13.5% of ImmuCell shares are held by institutional investors. 58.0% of Actuate Therapeutics shares are held by insiders. Comparatively, 5.7% of ImmuCell shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Actuate Therapeutics has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market. Comparatively, ImmuCell has a beta of 0.54, suggesting that its stock price is 46% less volatile than the broader market.

ImmuCell has higher revenue and earnings than Actuate Therapeutics. Actuate Therapeutics is trading at a lower price-to-earnings ratio than ImmuCell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actuate Therapeutics	N/A	N/A	-$22.23M	-$0.87	N/A
ImmuCell	$27.64M	3.29	-$1.04M	$0.08	125.25

In the previous week, ImmuCell had 1 more articles in the media than Actuate Therapeutics. MarketBeat recorded 1 mentions for ImmuCell and 0 mentions for Actuate Therapeutics. Actuate Therapeutics' average media sentiment score of 1.01 beat ImmuCell's score of 0.00 indicating that Actuate Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Actuate Therapeutics	Positive
ImmuCell	Neutral

Summary

ImmuCell beats Actuate Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Actuate Therapeutics compare to Nutriband?

Actuate Therapeutics (NASDAQ:ACTU) and Nutriband (NASDAQ:NTRB) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, analyst recommendations, valuation and media sentiment.

19.7% of Nutriband shares are owned by institutional investors. 58.0% of Actuate Therapeutics shares are owned by company insiders. Comparatively, 52.2% of Nutriband shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Nutriband has higher revenue and earnings than Actuate Therapeutics. Nutriband is trading at a lower price-to-earnings ratio than Actuate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actuate Therapeutics	N/A	N/A	-$22.23M	-$0.87	N/A
Nutriband	$1.62M	57.36	-$8.23M	-$0.53	N/A

In the previous week, Nutriband had 2 more articles in the media than Actuate Therapeutics. MarketBeat recorded 2 mentions for Nutriband and 0 mentions for Actuate Therapeutics. Actuate Therapeutics' average media sentiment score of 1.01 beat Nutriband's score of -0.09 indicating that Actuate Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Actuate Therapeutics	Positive
Nutriband	Neutral

Actuate Therapeutics has a beta of 0.95, indicating that its stock price is 5% less volatile than the broader market. Comparatively, Nutriband has a beta of 2.03, indicating that its stock price is 103% more volatile than the broader market.

Actuate Therapeutics has a net margin of 0.00% compared to Nutriband's net margin of -430.35%. Nutriband's return on equity of -109.07% beat Actuate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actuate Therapeutics	N/A	-346.19%	-178.40%
Nutriband	-430.35%	-109.07%	-95.54%

Actuate Therapeutics presently has a consensus target price of $10.50, indicating a potential upside of 1,444.12%. Given Actuate Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Actuate Therapeutics is more favorable than Nutriband.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actuate Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Nutriband	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

Nutriband beats Actuate Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Actuate Therapeutics compare to Aldeyra Therapeutics?

Actuate Therapeutics (NASDAQ:ACTU) and Aldeyra Therapeutics (NASDAQ:ALDX) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, media sentiment, valuation, profitability and risk.

Aldeyra Therapeutics' return on equity of -53.14% beat Actuate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actuate Therapeutics	N/A	-346.19%	-178.40%
Aldeyra Therapeutics	N/A	-53.14%	-34.94%

59.7% of Aldeyra Therapeutics shares are held by institutional investors. 58.0% of Actuate Therapeutics shares are held by company insiders. Comparatively, 11.8% of Aldeyra Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Actuate Therapeutics' average media sentiment score of 1.01 beat Aldeyra Therapeutics' score of 0.00 indicating that Actuate Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Actuate Therapeutics	Positive
Aldeyra Therapeutics	Neutral

Actuate Therapeutics currently has a consensus price target of $10.50, indicating a potential upside of 1,444.12%. Aldeyra Therapeutics has a consensus price target of $5.50, indicating a potential upside of 311.99%. Given Actuate Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Actuate Therapeutics is more favorable than Aldeyra Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actuate Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Aldeyra Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Actuate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actuate Therapeutics	N/A	N/A	-$22.23M	-$0.87	N/A
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.39	N/A

Actuate Therapeutics has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market. Comparatively, Aldeyra Therapeutics has a beta of 1.2, meaning that its share price is 20% more volatile than the broader market.

Summary

Actuate Therapeutics beats Aldeyra Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Actuate Therapeutics compare to Fortress Biotech?

Fortress Biotech (NASDAQ:FBIO) and Actuate Therapeutics (NASDAQ:ACTU) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, risk, media sentiment and valuation.

Fortress Biotech has a beta of 1.19, meaning that its stock price is 19% more volatile than the broader market. Comparatively, Actuate Therapeutics has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market.

Fortress Biotech presently has a consensus target price of $17.00, indicating a potential upside of 627.43%. Actuate Therapeutics has a consensus target price of $10.50, indicating a potential upside of 1,444.12%. Given Actuate Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Actuate Therapeutics is more favorable than Fortress Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fortress Biotech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Actuate Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Fortress Biotech has a net margin of 163.32% compared to Actuate Therapeutics' net margin of 0.00%. Fortress Biotech's return on equity of 83.47% beat Actuate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fortress Biotech	163.32%	83.47%	42.98%
Actuate Therapeutics	N/A	-346.19%	-178.40%

96.5% of Fortress Biotech shares are owned by institutional investors. 28.5% of Fortress Biotech shares are owned by insiders. Comparatively, 58.0% of Actuate Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Actuate Therapeutics' average media sentiment score of 1.01 beat Fortress Biotech's score of 0.00 indicating that Actuate Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Fortress Biotech	Neutral
Actuate Therapeutics	Positive

Fortress Biotech has higher revenue and earnings than Actuate Therapeutics. Actuate Therapeutics is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fortress Biotech	$63.26M	1.23	$6.82M	$2.64	0.89
Actuate Therapeutics	N/A	N/A	-$22.23M	-$0.87	N/A

Summary

Fortress Biotech beats Actuate Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Actuate Therapeutics compare to Verrica Pharmaceuticals?

Verrica Pharmaceuticals (NASDAQ:VRCA) and Actuate Therapeutics (NASDAQ:ACTU) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, profitability, valuation, analyst recommendations, institutional ownership, earnings and risk.

Actuate Therapeutics has a net margin of 0.00% compared to Verrica Pharmaceuticals' net margin of -102.84%. Actuate Therapeutics' return on equity of -346.19% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verrica Pharmaceuticals	-102.84%	-407.11%	-70.17%
Actuate Therapeutics	N/A	-346.19%	-178.40%

Verrica Pharmaceuticals has higher revenue and earnings than Actuate Therapeutics. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Actuate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verrica Pharmaceuticals	$30.32M	2.65	-$17.89M	-$1.67	N/A
Actuate Therapeutics	N/A	N/A	-$22.23M	-$0.87	N/A

42.5% of Verrica Pharmaceuticals shares are held by institutional investors. 52.9% of Verrica Pharmaceuticals shares are held by insiders. Comparatively, 58.0% of Actuate Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Verrica Pharmaceuticals has a beta of 1.49, indicating that its share price is 49% more volatile than the broader market. Comparatively, Actuate Therapeutics has a beta of 0.95, indicating that its share price is 5% less volatile than the broader market.

Verrica Pharmaceuticals currently has a consensus target price of $12.67, suggesting a potential upside of 171.06%. Actuate Therapeutics has a consensus target price of $10.50, suggesting a potential upside of 1,444.12%. Given Actuate Therapeutics' higher probable upside, analysts clearly believe Actuate Therapeutics is more favorable than Verrica Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Actuate Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Actuate Therapeutics' average media sentiment score of 1.01 beat Verrica Pharmaceuticals' score of 0.00 indicating that Actuate Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Verrica Pharmaceuticals	Neutral
Actuate Therapeutics	Positive

Summary

Verrica Pharmaceuticals and Actuate Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

Get Actuate Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACTU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACTU vs. The Competition

Export

Metric	Actuate Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$16.33M	$12.59B	$7.31B	$13.28B
Dividend Yield	N/A	2.63%	2.52%	12.56%
P/E Ratio	-0.78	792.28	274.07	25.70
Price / Sales	N/A	857.34	673.22	90.62
Price / Cash	N/A	88.64	77.80	52.76
Price / Book	2.00	10.58	10.38	6.32
Net Income	-$22.23M	$2.81B	$3.49B	$359.73M
7 Day Performance	-31.67%	-0.16%	-0.69%	0.17%
1 Month Performance	-44.72%	-1.38%	-3.19%	-3.27%
1 Year Performance	-90.31%	2.83%	15.12%	5.58%

Actuate Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACTU Actuate Therapeutics	2.907 of 5 stars	$0.68 -7.1%	$10.50 +1,444.1%	-89.4%	$16.33M	N/A	N/A	12	Positive News Analyst Forecast
ICCC ImmuCell	0.4891 of 5 stars	$9.65 +0.7%	N/A	+61.9%	$87.63M	$30.68M	120.63	73	Positive News
NTRB Nutriband	0.6783 of 5 stars	$6.88 +0.9%	N/A	+4.4%	$83.66M	$2.04M	N/A	3	News Coverage Upcoming Earnings Gap Down
ALDX Aldeyra Therapeutics	1.9074 of 5 stars	$1.38 +0.4%	$5.50 +300.0%	-73.6%	$82.95M	N/A	N/A	6
FBIO Fortress Biotech	1.8802 of 5 stars	$2.47 -1.0%	$17.00 +589.7%	-35.9%	$82.21M	$68.47M	0.93	78

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ACTU) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Actuate Therapeutics (ACTU) Competitors

ACTU vs. ICCC, NTRB, ALDX, FBIO, and VRCA

How does Actuate Therapeutics compare to ImmuCell?

Summary

How does Actuate Therapeutics compare to Nutriband?

Summary

How does Actuate Therapeutics compare to Aldeyra Therapeutics?

Summary

How does Actuate Therapeutics compare to Fortress Biotech?

Summary

How does Actuate Therapeutics compare to Verrica Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACTU vs. The Competition

Actuate Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Actuate Therapeutics (ACTU) Competitors

ACTU vs. ICCC, NTRB, ALDX, FBIO, and VRCA

How does Actuate Therapeutics compare to ImmuCell?

Is ACTU or ICCC more profitable?

Do analysts prefer ACTU or ICCC?

Do institutionals and insiders believe in ACTU or ICCC?

Which has more volatility & risk, ACTU or ICCC?

Which has preferable valuation & earnings, ACTU or ICCC?

Does the media refer more to ACTU or ICCC?

Summary

How does Actuate Therapeutics compare to Nutriband?

Do insiders and institutionals believe in ACTU or NTRB?

Which has stronger earnings and valuation, ACTU or NTRB?

Does the media favor ACTU or NTRB?

Which has more risk & volatility, ACTU or NTRB?

Is ACTU or NTRB more profitable?

Do analysts recommend ACTU or NTRB?

Summary

How does Actuate Therapeutics compare to Aldeyra Therapeutics?

Is ACTU or ALDX more profitable?

Do institutionals and insiders believe in ACTU or ALDX?

Does the media favor ACTU or ALDX?

Do analysts prefer ACTU or ALDX?

Which has higher valuation & earnings, ACTU or ALDX?

Which has more risk and volatility, ACTU or ALDX?

Summary

How does Actuate Therapeutics compare to Fortress Biotech?

Which has more risk and volatility, FBIO or ACTU?

Do analysts recommend FBIO or ACTU?

Is FBIO or ACTU more profitable?

Do institutionals & insiders believe in FBIO or ACTU?

Does the media prefer FBIO or ACTU?

Which has preferable earnings & valuation, FBIO or ACTU?

Summary

How does Actuate Therapeutics compare to Verrica Pharmaceuticals?

Is VRCA or ACTU more profitable?

Which has higher valuation & earnings, VRCA or ACTU?

Do insiders and institutionals hold more shares of VRCA or ACTU?

Which has more volatility and risk, VRCA or ACTU?

Do analysts rate VRCA or ACTU?

Does the media refer more to VRCA or ACTU?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACTU vs. The Competition

Actuate Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools